Pharma News
This Week
Nov 4, 2024
AstraZeneca supports initiative by American Lung Association to enhance quality of life for individuals with COPD
AstraZeneca has joined a campaign led by the American Lung Association (ALA) aimed at improving the quality of life for patients with chronic obstructive pulmonary disease (COPD). The "Learning to Live with COPD" initiative, supported by AstraZeneca, will provide education on the disease and treatment options. The campaign will focus on high-risk groups including women, those with lower socioeconomic status, and those in rural communities. With over 11.7 million diagnosed cases of COPD in the US and millions more potentially undiagnosed, the campaign aims to empower patients to better manage their condition and engage with healthcare providers.
Nov 4, 2024
Novo unveils highly effective new obesity drug, report says
Novo Nordisk, the pharmaceutical company behind the weight loss drug semaglutide, is developing a new medication called CagriSema that combines semaglutide and cagrilintide. In clinical trials, CagriSema helped patients lose 15.6% of their body weight. It is currently undergoing a Phase III trial against Eli Lilly's Zepbound. The drugs work by slowing down the movement of food through the stomach and curbing appetite. Despite some side effects, these drugs have been successful in promoting weight loss.
Nov 4, 2024
Novo's semaglutide, a major drug for obesity, set to receive label extension in Europe - European Biotechnology
Danish pharmaceutical company Novo Nordisk has released preliminary Phase III data from a study evaluating the efficacy of the drug semaglutide in adults with metabolic dysfunction-associated steatohepatitis (MASH) and advanced liver fibrosis. The results showed that semaglutide met all primary endpoints, with a significant percentage of patients experiencing improvement in liver fibrosis and resolution of steatohepatitis. Novo Nordisk plans to submit marketing authorization applications in the US and EU by the first half of 2025. The study is set to continue until 2029 to demonstrate long-term efficacy.
